Cranberry fruit powder (FlowensTM) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33161875" target="_blank" >RIV/61989592:15110/16:33161875 - isvavai.cz</a>

Výsledek na webu

<a href="https://link.springer.com/article/10.1007%2Fs00345-015-1611-7" target="_blank" >https://link.springer.com/article/10.1007%2Fs00345-015-1611-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00345-015-1611-7" target="_blank" >10.1007/s00345-015-1611-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cranberry fruit powder (FlowensTM) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.

Popis výsledku v původním jazyce

Background Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust ef cacy studies. Methods This 6-month, randomized, double-blind, pla- cebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (FlowensTM) on LUTS and uro owmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an inter- national prostate symptoms score (IPSS) score GREATER-THAN OR EQUAL TO8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary out- come measures included quality of life, bladder volume (Vol), maximum urinary ow rate (Qmax), average urinary ow rate (Qave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-speci c antigen, sele- nium, interleukin 6, and C-reactive protein at 6 months. Results After 6 months, subjects in both FlowensTM groups had a lower IPSS (MINUS SIGN 3.1 and MINUS SIGN 4.1 in the 250- and * Emilie Fromentin e.fromentin@naturex.com 500-mg groups, p = 0.05 and p < 0.001, respectively) ver- sus the placebo group (MINUS SIGN 1.5), and a dose-response effect was observed. There were signi cant differences in Qmax, Qave, PVR, and Vol in the FlowensTM 500-mg group ver- sus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. Conclusions FlowensTM showed a clinically relevant, dose-dependent, and signi cant reduction in LUTS in men over 45.

Název v anglickém jazyce

Cranberry fruit powder (FlowensTM) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.

Popis výsledku anglicky

Background Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust ef cacy studies. Methods This 6-month, randomized, double-blind, pla- cebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (FlowensTM) on LUTS and uro owmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an inter- national prostate symptoms score (IPSS) score GREATER-THAN OR EQUAL TO8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary out- come measures included quality of life, bladder volume (Vol), maximum urinary ow rate (Qmax), average urinary ow rate (Qave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-speci c antigen, sele- nium, interleukin 6, and C-reactive protein at 6 months. Results After 6 months, subjects in both FlowensTM groups had a lower IPSS (MINUS SIGN 3.1 and MINUS SIGN 4.1 in the 250- and * Emilie Fromentin e.fromentin@naturex.com 500-mg groups, p = 0.05 and p < 0.001, respectively) ver- sus the placebo group (MINUS SIGN 1.5), and a dose-response effect was observed. There were signi cant differences in Qmax, Qave, PVR, and Vol in the FlowensTM 500-mg group ver- sus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. Conclusions FlowensTM showed a clinically relevant, dose-dependent, and signi cant reduction in LUTS in men over 45.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

World Journal of Urology

ISSN

0724-4983

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

6

Strana od-do

419-424

Kód UT WoS článku

000371052400017

EID výsledku v databázi Scopus

—